세계의 사이클로스포린 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Cyclosporine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

US $ 3,920 ￦ 5,555,000

PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 4,730 ￦ 6,702,000

PDF & Excel (10-user License)

PDF 및 Excel 보고서를 동일 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 7,430 ￦ 10,529,000

PDF & Excel (Corporate User License)

PDF 및 Excel 보고서를 동일 기업 내 모든 사용자가 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

한글목차

세계의 사이클로스포린 시장은 상당한 성장을 이루었으며, 시장 규모는 2024년 37억 8,000만 달러에서 2033년에는 131억 3,000만 달러로 급증하고, 예측 기간 동안 연평균 성장률(CAGR)은 14.82%로 견조한 증가세를 보일 것으로 예상됩니다.

세계 사이클로스포린 시장은 장기 이식 및 자가면역질환의 면역억제요법에서 중요한 역할을 담당하고 있어 안정적인 성장이 예상됩니다. 서방형 제제, 국소 투여 시스템 등 제제 기술의 발전으로 치료 효과와 환자 순응도가 향상되고 있습니다. 향후 부작용을 줄이고 장기적인 결과를 개선할 수 있는 새로운 유사 약물 및 병용요법이 주목받고 있습니다.

또한, 피부과와 안과에서의 적응증 확대로 시장에서의 적용 범위가 넓어지고 있습니다. 약물유전체학과 맞춤의료 접근법의 통합으로 투여 요법의 최적화와 부작용의 최소화가 이루어지고 있습니다. 의료 인프라에 대한 투자가 증가하고 있는 신흥 시장에서는 사이클로스포린 치료에 대한 접근성이 향상되고 있습니다. 연구의 발전과 함께 사이클로스포린 시장은 혁신을 계속하여 보다 안전하고 효과적인 면역 억제 요법을 제공할 것입니다.

목차

제1장 서문

제2장 주요 요약

• 시장 하이라이트
• 세계 시장 현황

제3장 사이클로스포린 - 산업 분석

• 소개 : 시장 역학
• 시장 성장 촉진요인
• 시장 성장 억제요인
• 기회
• 업계 동향
• Porter's Five Forces 분석
• 시장 매력 분석

제4장 밸류체인 분석

• 밸류체인 분석
• 원재료 분석
  • 원재료 리스트
  • 원재료 제조업체 리스트
  • 주요 원재료 가격 동향
• 잠재적 바이어 리스트
• 마케팅 채널
  • 직접 마케팅
  • 간접 마케팅
  • 마케팅 채널 발전 동향

제5장 사이클로스포린 세계 시장 분석 : 적응증별

• 적응증별 개요
• 적응증별, 과거 및 예측 데이터 분석
• 이식 거부반응 예방
• 류마티스 관절염
• 건선
• 자가면역성 중증근무력증
• 안구건조증
• 기타 적응증

제6장 사이클로스포린 세계 시장 분석 : 제형별

• 제형별 개요
• 제형별, 과거 및 예측 데이터 분석
• 캡슐
• 점안제
• 액제
• 크림·연고

제7장 사이클로스포린 세계 시장 분석 : 투여 경로별

• 투여 경로별 개요
• 투여 경로별, 과거 및 예측 데이터 분석
• 경구제
• 국소
• 비경구

제8장 사이클로스포린 세계 시장 분석 : 유통 채널별

• 유통 채널별 개요
• 유통 채널별, 과거 및 예측 데이터 분석
• 병원 약국
• 소매 약국
• 온라인 약국

제9장 사이클로스포린 세계 시장 분석 : 지역별

• 지역별 전망
• 소개
• 북미 매출 분석
  • 개요, 실적과 예측
  • 북미 : 부문별
  • 북미 국가별
  • 미국
  • 캐나다
  • 멕시코
• 유럽 매출 분석
  • 개요, 실적과 예측
  • 유럽 : 부문별
  • 유럽 국가별
  • 영국
  • 프랑스
  • 독일
  • 이탈리아
  • 러시아
  • 기타 유럽
• 아시아태평양 매출 분석
  • 개요, 실적과 예측
  • 아시아태평양 : 부문별
  • 아시아태평양 국가별
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주
  • 동남아시아
  • 기타 아시아태평양
• 라틴아메리카 매출 분석
  • 개요, 실적과 예측
  • 라틴아메리카 : 부문별
  • 라틴아메리카 국가별
  • 브라질
  • 아르헨티나
  • 페루
  • 칠레
  • 기타 라틴아메리카
• 중동 및 아프리카 매출 분석
  • 개요, 실적과 예측
  • 중동 및 아프리카 : 부문별
  • 중동 및 아프리카 국가별 리스트
  • 사우디아라비아
  • 아랍에미리트
  • 이스라엘
  • 남아프리카공화국
  • 기타 중동 및 아프리카

제10장 사이클로스포린 기업 경쟁 구도

• 사이클로스포린 시장 경쟁
• 제휴, 협력, 합의
• 인수합병
• 신제품 출시
• 기타 개발

제11장 기업 개요

• 상위 기업의 시장 점유율 분석
• 시장 집중도
• Avet Pharmaceuticals
• AdvaCare Pharma
• AbbVie
• Apotex
• Cipla
• Dr. Reddy'S Laboratories
• Novartis
• Santen Pharmaceutical
• Sun Pharmaceutical Industries
• Strides Pharma Science Limited
• Teva Pharmaceutical Industries
• Viatris

KSM

영문 목차

영문목차

Global Cyclosporine Market is poised for a significant growth, with market size projected to surge from USD 3.78 Billion in 2024 to USD 13.13 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 14.82% during the forecast period.

The global cyclosporine market is expected to grow steadily, driven by its critical role in immunosuppressive therapy for organ transplantation and autoimmune diseases. Advances in formulation technologies, including sustained-release and topical delivery systems, are enhancing therapeutic efficacy and patient compliance. Future developments will focus on novel analogs and combination therapies that reduce side effects and improve long-term outcomes.

Additionally, expanding indications in dermatology and ophthalmology are broadening market applications. The integration of pharmacogenomics and personalized medicine approaches is optimizing dosing regimens and minimizing adverse reactions. Emerging markets with increasing healthcare infrastructure investments are improving access to cyclosporine therapies. As research progresses, the cyclosporine market will continue to innovate, delivering safer and more effective immunosuppressive treatments.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Cyclosporine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Indication

• Transplant Rejection Prophylaxis
• Rheumatoid Arthritis
• Psoriasis
• Autoimmune Myasthenia Gravis
• Dry Eye
• Other Indications

By Dosage Form

• Capsule
• Eye Drops
• Liquid Solutions
• Creams And Ointments

By Route Of Administration

• Oral
• Topical
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• List of Companies Profiled in the report
• Avet Pharmaceuticals, AdvaCare Pharma, AbbVie, Apotex, Cipla, Dr. Reddy's Laboratories, Novartis, Santen Pharmaceutical, Sun Pharmaceutical Industries, Strides Pharma Science Limited, Teva Pharmaceutical Industries, Viatris

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. CYCLOSPORINE - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Indication
  • 3.7.2 Market Attractiveness Analysis By Dosage Form
  • 3.7.3 Market Attractiveness Analysis By Route of Administration
  • 3.7.4 Market Attractiveness Analysis By Distribution Channel
  • 3.7.5 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CYCLOSPORINE MARKET ANALYSIS BY INDICATION

• 5.1. Overview By Indication
• 5.2. Historical and Forecast Data Analysis By Indication
• 5.3. Transplant rejection prophylaxis Historic and Forecast Sales By Regions
• 5.4. Rheumatoid arthritis Historic and Forecast Sales By Regions
• 5.5. Psoriasis Historic and Forecast Sales By Regions
• 5.6. Autoimmune myasthenia gravis Historic and Forecast Sales By Regions
• 5.7. Dry eye Historic and Forecast Sales By Regions
• 5.8. Other indications Historic and Forecast Sales By Regions

6. GLOBAL CYCLOSPORINE MARKET ANALYSIS BY DOSAGE FORM

• 6.1. Overview By Dosage Form
• 6.2. Historical and Forecast Data Analysis By Dosage Form
• 6.3. Capsule Historic and Forecast Sales By Regions
• 6.4. Eye drops Historic and Forecast Sales By Regions
• 6.5. Liquid solutions Historic and Forecast Sales By Regions
• 6.6. Creams and ointments Historic and Forecast Sales By Regions

7. GLOBAL CYCLOSPORINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 7.1. Overview By Route of Administration
• 7.2. Historical and Forecast Data Analysis By Route of Administration
• 7.3. Oral Historic and Forecast Sales By Regions
• 7.4. Topical Historic and Forecast Sales By Regions
• 7.5. Parenteral Historic and Forecast Sales By Regions

8. GLOBAL CYCLOSPORINE MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 8.1. Overview By Distribution Channel
• 8.2. Historical and Forecast Data Analysis By Distribution Channel
• 8.3. Hospital pharmacies Historic and Forecast Sales By Regions
• 8.4. Retail pharmacies Historic and Forecast Sales By Regions
• 8.5. Online pharmacies Historic and Forecast Sales By Regions

9. GLOBAL CYCLOSPORINE MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE CYCLOSPORINE COMPANIES

• 10.1. Cyclosporine Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF CYCLOSPORINE INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Avet Pharmaceuticals
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. AdvaCare Pharma
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. AbbVie
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Apotex
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Cipla
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Dr. Reddy'S Laboratories
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Novartis
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Santen Pharmaceutical
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Sun Pharmaceutical Industries
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Strides Pharma Science Limited
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Teva Pharmaceutical Industries
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments
• 11.14. Viatris
  • 11.14.1 Company Overview
  • 11.14.2 Company Revenue
  • 11.14.3 Products
  • 11.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies

관련자료